Eur J Orthop Surg Traumatol
April 2018
Background: Different cell populations from bone marrow were used in various clinical trials for cardiac diseases during last decade. Four clinical studies are ongoing in our institution and enroll patients with cardiac diseases, coronary disease, type 2 diabetes, and osteoarthritis. The density gradient is used to separate bone marrow mononuclear cells.
View Article and Find Full Text PDFRecently we developed amthamine [2-amino-5-(2-aminoethyl)-4-methylthiazole]. This cyclic analogue of dimaprit proved to be the most potent and selective histamine H2 receptor agonist of a series of substituted 4- or 5-(2-aminoethyl)thiazoles. Quantum chemical studies on histamine (N pi-H tautomer), dimaprit, and amthamine revealed that, based upon geometries of molecular electrostatic potentials, it is likely that these agonists accept a proton from the proton-donating receptor site on their double-bonded (heteroaromatic) nitrogen atoms.
View Article and Find Full Text PDFIt is well known that both histamine and dimaprit show moderate histamine H2-receptor agonistic activities on the guinea pig right atrium. Quantum chemical calculations on these two compounds showed similarities in electron distributions and molecular electrostatic potentials (MEP's), which could be extended to rigid analogues [2-amino-5-(2-aminoethyl)thiazoles] of the latter structure. On the base of these results a series of substituted 4- and 5-(2-aminoethyl)thiazoles was synthesized applying small alkyl substitution variations as reported for histamine.
View Article and Find Full Text PDFIt is well known that both histamine and dimaprit show moderate H2-receptor agonistic activity (guinea pig right atrium). Quantum chemical calculations indicated that 2-aminothiazole derivatives that might be regarded as cyclic dimaprit analogues, should possess H2-receptor agonistic activity as well. In the present study a series of 4- or 5-(omega-aminoalkyl) thiazoles has been synthesized, showing a moderate to strong H2-receptor agonistic activity as compared to histamine whereas no activity on H1- and H3-receptors could be detected.
View Article and Find Full Text PDFThe N'-(4-1H-imidazol-4-ylphenyl)formamidines were recently introduced as a new class of active H2 antagonists; the authors of the compounds (Donetti et al. of de Angeli, Italy) have suggested that these compounds interact with the H2 receptor through their monocations. This is at variance with the model proposed for cimetidine by the SK&F (Smith Kline & French, UK) group who proposed the neutral molecule as the species active at the H2 receptor.
View Article and Find Full Text PDF